The U.S. FDA has concluded inspection of Company's Goa facility. The inspection of the facility took place between 25th February to 6 th March 2019, resulting in a Form 483 with eight observations. None of these observations are considered either critical or repetitive in nature. Company is highly confident of closing these expeditiously and remains committed to global standards of quality & compliance. The site will continue to supply to the US markets all approved ANDA's. This inspection will help Company to received pending ANDA's approval alredy filed by it.
Shares of MARKSANS PHARMA LTD. was last trading in BSE at Rs.26.8 as compared to the previous close of Rs. 27.4. The total number of shares traded during the day was 367131 in over 882 trades.
The stock hit an intraday high of Rs. 28.1 and intraday low of 26.45. The net turnover during the day was Rs. 9979137.